Morgan Stanley Increases Edwards Lifesciences (NYSE:EW) Pric

Edwards Lifesciences (NYSE:EW – Free Report) had its price target hoisted by Morgan Stanley from $95.00 to $103.00 in a research report sent to investors on Thursday, Benzinga reports. The firm currently has an overweight rating on the medical research company’s stock. Several other analysts have also commented on the stock. Royal Bank of Canada […]

Related Keywords

United States , Canada , Japan , Danielj Lippis , Catherinem Szyman , Edwards Lifesciences , Wahed Invest , Cove Private Wealth , Morgan Stanley , Vanguard Group Inc , Edwards Lifesciences Company Profile , Accent Capital Management , Royal Bank , Edwards Lifesciences Corporation , Citigroup , Willner Heller , Wolfe Research , Securities Exchange Commission , Free Report , Get Free Report , Exchange Commission , Capital Management , Private Wealth , Lifesciences Corporation , Edwards Lifesciences Daily ,